Literature DB >> 12799446

Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.

Arnold Grünweller1, Eliza Wyszko, Birgit Bieber, Ricarda Jahnel, Volker A Erdmann, Jens Kurreck.   

Abstract

Locked nucleic acids (LNAs) and double-stranded small interfering RNAs (siRNAs) are rather new promising antisense molecules for cell culture and in vivo applications. Here, we compare LNA-DNA-LNA gapmer oligonucleotides and siRNAs with a phosphorothioate and a chimeric 2'-O-methyl RNA-DNA gapmer with respect to their capacities to knock down the expression of the vanilloid receptor subtype 1 (VR1). LNA-DNA-LNA gapmers with four or five LNAs on either side and a central stretch of 10 or 8 DNA monomers in the center were found to be active gapmers that inhibit gene expression. A comparative co-transfection study showed that siRNA is the most potent inhibitor of VR1-green fluorescent protein (GFP) expression. A specific inhibition was observed with an estimated IC50 of 0.06 nM. An LNA gapmer was found to be the most efficient single-stranded antisense oligonucleotide, with an IC50 of 0.4 nM being 175-fold lower than that of commonly used phosphorothioates (IC50 approximately 70 nM). In contrast, the efficiency of a 2'-O-methyl-modified oligonucleotide (IC50 approximately 220 nM) was 3-fold lower compared with the phosphorothioate. The high potency of siRNAs and chimeric LNA-DNA oligonucleotides make them valuable candidates for cell culture and in vivo applications targeting the VR1 mRNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799446      PMCID: PMC162243          DOI: 10.1093/nar/gkg409

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  44 in total

Review 1.  RNA interference: listening to the sound of silence.

Authors:  P D Zamore
Journal:  Nat Struct Biol       Date:  2001-09

2.  Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I.

Authors:  Jens Kurreck; Birgit Bieber; Ricarda Jahnel; Volker A Erdmann
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

3.  Antisense and sensibility.

Authors:  Alan Dove
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

Review 4.  The TRP channels, a remarkably functional family.

Authors:  Craig Montell; Lutz Birnbaumer; Veit Flockerzi
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

Review 5.  Application of PNA and LNA oligomers to chemotherapy.

Authors:  A N Elayadi; D R Corey
Journal:  Curr Opin Investig Drugs       Date:  2001-04

6.  The experimental use of antisense oligonucleotides: a guide for the perplexed.

Authors:  C A Stein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

7.  The cloned capsaicin receptor integrates multiple pain-producing stimuli.

Authors:  M Tominaga; M J Caterina; A B Malmberg; T A Rosen; H Gilbert; K Skinner; B E Raumann; A I Basbaum; D Julius
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

8.  Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides.

Authors:  A Arzumanov; A P Walsh; V K Rajwanshi; R Kumar; J Wengel; M J Gait
Journal:  Biochemistry       Date:  2001-12-04       Impact factor: 3.162

9.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

Review 10.  Novel antisense and peptide nucleic acid strategies for controlling gene expression.

Authors:  Dwaine A Braasch; David R Corey
Journal:  Biochemistry       Date:  2002-04-09       Impact factor: 3.162

View more
  63 in total

Review 1.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

2.  Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity.

Authors:  Bryan A Kraynack; Brenda F Baker
Journal:  RNA       Date:  2005-11-21       Impact factor: 4.942

3.  Gene silencing by synthetic U1 adaptors.

Authors:  Rafal Goraczniak; Mark A Behlke; Samuel I Gunderson
Journal:  Nat Biotechnol       Date:  2009-02-15       Impact factor: 54.908

4.  Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Authors:  Michael A Collingwood; Scott D Rose; Lingyan Huang; Chris Hillier; Mohammad Amarzguioui; Merete T Wiiger; Harris S Soifer; John J Rossi; Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-06

5.  PEI-complexed LNA antiseeds as miRNA inhibitors.

Authors:  Maren Thomas; Kerstin Lange-Grünweller; Eyas Dayyoub; Udo Bakowsky; Ulrike Weirauch; Achim Aigner; Roland K Hartmann; Arnold Grünweller
Journal:  RNA Biol       Date:  2012-08-01       Impact factor: 4.652

6.  New Noncoding Lytic Transcripts Derived from the Epstein-Barr Virus Latency Origin of Replication, oriP, Are Hyperedited, Bind the Paraspeckle Protein, NONO/p54nrb, and Support Viral Lytic Transcription.

Authors:  Subing Cao; Walter Moss; Tina O'Grady; Monica Concha; Michael J Strong; Xia Wang; Yi Yu; Melody Baddoo; Kun Zhang; Claire Fewell; Zhen Lin; Yan Dong; Erik K Flemington
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

Review 7.  Diverse Applications of Nanomedicine.

Authors:  Beatriz Pelaz; Christoph Alexiou; Ramon A Alvarez-Puebla; Frauke Alves; Anne M Andrews; Sumaira Ashraf; Lajos P Balogh; Laura Ballerini; Alessandra Bestetti; Cornelia Brendel; Susanna Bosi; Monica Carril; Warren C W Chan; Chunying Chen; Xiaodong Chen; Xiaoyuan Chen; Zhen Cheng; Daxiang Cui; Jianzhong Du; Christian Dullin; Alberto Escudero; Neus Feliu; Mingyuan Gao; Michael George; Yury Gogotsi; Arnold Grünweller; Zhongwei Gu; Naomi J Halas; Norbert Hampp; Roland K Hartmann; Mark C Hersam; Patrick Hunziker; Ji Jian; Xingyu Jiang; Philipp Jungebluth; Pranav Kadhiresan; Kazunori Kataoka; Ali Khademhosseini; Jindřich Kopeček; Nicholas A Kotov; Harald F Krug; Dong Soo Lee; Claus-Michael Lehr; Kam W Leong; Xing-Jie Liang; Mei Ling Lim; Luis M Liz-Marzán; Xiaowei Ma; Paolo Macchiarini; Huan Meng; Helmuth Möhwald; Paul Mulvaney; Andre E Nel; Shuming Nie; Peter Nordlander; Teruo Okano; Jose Oliveira; Tai Hyun Park; Reginald M Penner; Maurizio Prato; Victor Puntes; Vincent M Rotello; Amila Samarakoon; Raymond E Schaak; Youqing Shen; Sebastian Sjöqvist; Andre G Skirtach; Mahmoud G Soliman; Molly M Stevens; Hsing-Wen Sung; Ben Zhong Tang; Rainer Tietze; Buddhisha N Udugama; J Scott VanEpps; Tanja Weil; Paul S Weiss; Itamar Willner; Yuzhou Wu; Lily Yang; Zhao Yue; Qian Zhang; Qiang Zhang; Xian-En Zhang; Yuliang Zhao; Xin Zhou; Wolfgang J Parak
Journal:  ACS Nano       Date:  2017-03-14       Impact factor: 15.881

Review 8.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

9.  Therapeutic potential of RNA interference in pain medicine.

Authors:  Ping-Heng Tan; Lin-Cheng Yang; Ru-Rong Ji
Journal:  Open Pain J       Date:  2009-01-01

10.  Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model.

Authors:  Liu Si Lan; Yang Jian Ping; Wang Li Na; Jiang Miao; Qiu Qiao Cheng; Ma Zhen Ni; Liu Lei; Li Cai Fang; Ren Chun Guang; Zhou Jin; Li Wei
Journal:  Mol Pain       Date:  2010-01-20       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.